Clik here to view.
急性出血中と急速輸液後におけるMasimo SpHb®の性能を検討する新研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、エジプトのカイロ大学の研究者らが最近公表した研究の知見について発表しました。この研究は、急性出血中と急速輸液後に、マシモの非侵襲的かつ連続的なヘモグロビン測定値（SpHb®）を検査室での侵襲的ヘモグロビン測定値（Lab-Hb）と比較したものです1。...
View ArticleClik here to view.
Alexion Announces Positive Top-Line Results Showing Successful Phase 3...
NEW HAVEN, Conn. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor,...
View ArticleClik here to view.
Tokai-Denshi Developed A.I.-Equipped Portable Odor Detector/Identifier...
FUJI, Japan Tokai-Denshi Inc. and The Shizuoka Cancer Center Research Institute jointly developed an A.I.-based Portable Odor detector/Identifier which analyzes malodorous components emitted from...
View ArticleClik here to view.
Cellvizio® Obtains Positive Assessment from the Korean National...
PARIS Regulatory News: Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based confocal laser endomicroscopy (pCLE) platform, today announced...
View ArticleClik here to view.
Foundation Medicine Advances Patient Access to Precision Medicine; Pursues...
CAMBRIDGE, Mass. Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), one of Japan’s leading research-based pharmaceutical companies and a...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Levocetirizine...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an...
View ArticleClik here to view.
AVITA Medical Announces Government Funded Clinical Trial of RECELL® in China
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY) today announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep...
View ArticleClik here to view.
U.S. FDA Grants Priority Review for a Supplemental New Drug Application...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New Drug Application (sNDA)...
View ArticleClik here to view.
Notification That All Shares of Hakushindo Pharmaceutical Have Been Acquired...
TOKYO Shinkowa Pharmaceutical Co., Ltd., (Head Office: Chuo-ku, Tokyo, CEO: Megumi Tanaka) whose goal is to achieve productive aging around the world, has acquired all shares of Hakushindo...
View ArticleClik here to view.
To Accelerate Research on Anti-aging and Age-related Disease,In Light of the...
TOKYO Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo, CEO Daizo Shimamura) provided research funding to the Project Research Center For Clinical Trials and Preventative...
View ArticleClik here to view.
Morinaga Milk’s New Probiotic Strain, Bifidobacterium breve A1, May Prevent...
TOKYO Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic...
View ArticleClik here to view.
药明生物新建商业化生产基地将安装ABEC生产的最大一次性生物反应器
中国无锡、美国宾夕法尼亚州伯利恒市 (美国商业资讯)–全球领先的生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，将在公司正在筹建的商业化生产基地（药明生物四厂）安装美国知名生产设备供应商ABEC公司4,000升Custom Single Run（CSR®）一次性反应器。在此之前，药明生物已成功测试和评估了ABEC公司的CSR生物反应器技术。...
View ArticleClik here to view.
BIRAC and PerkinElmer Sign Letter of Intent to Promote India-Led Startups and...
NEW DELHI The Biotechnology Industry Research Assistance Council (BIRAC) celebrated its 6th Foundation Day on Tuesday in New Delhi. The event, aptly themed ‘Sustaining Innovation: A Market Driven...
View ArticleClik here to view.
AVITA Medical Announces MIHS Burn Center Press Conference Regarding RECELL®...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX – AVH, OTCQX: AVMXY) announced that Maricopa Integrated Health System (MIHS) Burn Center will hold a press conference today to...
View ArticleClik here to view.
森永乳业的新款益生菌菌株短双歧杆菌A1或可预防阿尔茨海默病发病
东京 (美国商业资讯) — 日本领先的乳制品公司森永乳业株式会社(TOKYO:2264)今天发布了一项研究成果，该研究调查该公司新款益生菌菌株短双歧杆菌A1在一个阿尔茨海默病模型中的预防效应。研究人员发现，短双歧杆菌A1可改善认知缺陷小鼠的空间识别能力以及学习和记忆能力，这表明该菌株对预防人类发生阿尔茨海默病或许有重要作用1。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Co-Diagnostics, Inc. Announces Construction Update at JV Manufacturing...
SALT LAKE CITY Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today an update on the Joint...
View ArticleClik here to view.
Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in...
View ArticleClik here to view.
AVITA Medical Announces RECELL® Health Economic Model to be Presented at...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that an abstract highlighting an economic model demonstrating the cost benefit of RECELL® in the...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Palonosetron Hydrochloride...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/...
View ArticleClik here to view.
武田宣布发表ICLUSIG® (ponatinib)枢纽性2期PACE血液病试验的终局数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，《血液》杂志发表ICLUSIG (ponatinib)治疗难治性慢性粒细胞性白血病(CML)或费城染色体阳性急性淋巴细胞性白血病(Ph+...
View Article